

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2566)

**INSIDE INFORMATION
GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE
FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION**

The announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the **“Company”**) pursuant to Rule 13.09(2)(a) of the Rules (the **“Listing Rules”**) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the **“Inside Information Provisions”**).

References are made to (i) the announcement of the Company dated December 2, 2025 in relation to, among other things, proposed implementation of the H Share Full Circulation; and (ii) the announcement of the Company dated April 2, 2026 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company (collectively, the **“Announcements”**). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL BY THE STOCK EXCHANGE

The Board is pleased to announce that the Company has applied to the Listing Committee of the Stock Exchange for the approval (the **“Listing Approval”**) of the listing (the **“Listing”**) of 136,302,015 H shares (the **“Converted H Shares”**) of the Company to be converted under the conversion of 136,302,015 Unlisted Shares (the **“Conversion”**) held by 12 participating shareholders of the Company (the **“Participating Shareholders”**) and the permission to deal in the Converted H Shares. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on May 8, 2026.

SHAREHOLDING STRUCTURE

The number of the Converted H Shares held by the Participating Shareholders represents approximately 56.44% of the total issued Shares (excluding the treasury Shares) as at the date of this announcement. The details of the Participating Shareholders and their respective Unlisted Shares to be converted into H Shares are as follows:

		Number of Unlisted Shares to be converted into H Shares	Percentage of the H Share Full Circulation in the total share capital ^{Notes (1) & (2)}
Name of Participating Shareholders			
1	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有限公司)	29,484,317	12.21%
2	Hangzhou Huasheng Pharmaceutical Group Co., Ltd. (杭州華昇醫藥集團有限公司)	25,998,521	10.76%
3	CORPORACION QUIMICOFARMACEUTICA ESTEVE, SOCIEDAD ANÓNIMA	24,000,000	9.94%
4	Hangzhou Investment Holdings Co., Ltd. (杭州市金融投資集團有限公司)	17,429,338	7.22%
5	Zhejiang Wangxin Technology Venture Capital Co., Ltd. (浙江網新科技創投有限公司)	12,256,887	5.07%
6	Highland Pharma Limited	7,000,000	2.90%
7	Wan Liyang Group Co., Ltd. (萬里揚集團有限公司)	4,900,000	2.03%
8	Wu Qiyuan (吳啟元)	4,071,580	1.69%
9	Chengheda (Hangzhou) Enterprise Management Partnership (誠和達(杭州)企業管理合夥企業(有限合夥))	3,477,904	1.44%
10	Hangzhou Nanbeiju Enterprise Management Partnership (Limited Partnership) (杭州南北聚企業管理合夥企業(有限合夥))	3,285,425	1.36%
11	Li Bangliang (李邦良)	2,333,184	0.97%
12	Hangzhou Qingfanghao Enterprise Management Partnership (Limited Partnership) (杭州晴方好企業管理合夥企業(有限合夥))	2,064,859	0.85%
Total		136,302,015	56.44%

Notes:

- (1) The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.
- (2) The calculation is based on the number of 241,516,400 Shares (excluding 3,882,400 treasury Shares) as of the date of this announcement.

Immediately before and upon completion of the Conversion and the Listing, all Unlisted Shares will have been converted into H Shares, and the issued share capital of the Company will comprise 245,398,800 H Shares.

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and the Listing in compliance with the requirements under the Listing Rules and applicable laws, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, May 8, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.